PA5-30594

antibody from Invitrogen Antibodies

Targeting: ABCC1 GS-X, MRP, MRP1

Western blot (Data presented on provider website)

Immunohistochemistry (Data presented on provider website)

Other assay (Supportive data in Antibodypedia)

Antibody Data

Product number

PA5-30594

Provider

Invitrogen Antibodies

Product name

MRP1 Polyclonal Antibody

Antibody type

Polyclonal

Antigen

Synthetic peptide

Description

Recommended positive controls: A431. Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.

Reactivity

Human

Host

Rabbit

Isotype

IgG

Vial size

100 µL

Concentration

1.73 mg/mL

Storage

Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.

References

Submitted references

Metformin inhibits proliferation and enhances chemosensitivity of intrahepatic cholangiocarcinoma cell lines.

Ling S, Feng T, Ke Q, Fan N, Li L, Li Z, Dong C, Wang C, Xu F, Li Y, Wang L
Oncology reports 2014 Jun;31(6):2611-8

---

Metformin reverses multidrug resistance in human hepatocellular carcinoma Bel‑7402/5‑fluorouracil cells.

Ling S, Tian Y, Zhang H, Jia K, Feng T, Sun D, Gao Z, Xu F, Hou Z, Li Y, Wang L
Molecular medicine reports 2014 Dec;10(6):2891-7

Other assay

Supportive validation

Submitted by

Invitrogen Antibodies (provider)

Main image

Experimental details

Figure 5 Met affects the expression of HIF-1alpha, MDR1/P-gp and MRP1. (A) Reverse transcription-polymerase chain reaction analysis of MDR1 and MRP1 expression in the different treatment groups. (B) Western blot analysis of HIF-1alpha, MDR1 and MRP1 in the different treatment groups. (C-E) Relative density of the western blotting bands demonstrated that levels of HIF-1alpha, P-gp and MRP1 decreased with increasing concentrations of Met in a dose-dependent manner, with a statistically significant difference between the treatments and the controls ( ** P